Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study
2010

Predicting Lupus Flares with Mycophenolate Mofetil Levels

Sample size: 26 publication 10 minutes Evidence: moderate

Author Information

Author(s): Djabarouti Sarah, Breilh Dominique, Duffau Pierre, Lazaro Estibaliz, Greib Carine, Caubet Olivier, Saux Marie-Claude, Pellegrin Jean-Luc, Viallard Jean-François

Primary Institution: Université Victor Segalen Bordeaux 2, Hôpital Haut-Lévêque, CHU de Bordeaux

Hypothesis

Can mycophenolate mofetil pharmacokinetics predict clinical flares in systemic lupus erythematosus patients?

Conclusion

Lower mycophenolate mofetil levels are associated with increased risk of clinical flares in lupus patients.

Supporting Evidence

  • Patients with lower mycophenolate levels had a higher rate of disease flares.
  • A threshold of 3 mg/L for mycophenolate levels predicted flares with 92% negative predictive value.
  • The study followed patients for six months to assess clinical outcomes.

Takeaway

Doctors can tell if lupus patients might have a flare by checking their medicine levels. If the levels are too low, it could mean trouble.

Methodology

The study measured drug levels in blood samples from lupus patients and tracked their disease activity over six months.

Potential Biases

Potential bias due to the observational nature of the study and the exclusion of patients with renal involvement.

Limitations

The study had a small sample size and was conducted at a single center, which may limit the generalizability of the findings.

Participant Demographics

26 Caucasian patients with systemic lupus erythematosus, without renal manifestations.

Statistical Information

P-Value

0.003

Confidence Interval

95% CI 0.71 to 1

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/ar3202

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication